Key Takeaways

A clinical trial matching service reviews your specific diagnosis and treatment history against currently open, registered trials — it exists because no single hospital runs every trial, and no public database filters results down to "trials you actually qualify for."

Matching identifies candidates; it does not enroll you. The hospital running the trial makes the final eligibility decision, based on the protocol's own criteria.

It is not the same as finding a commercial cancer treatment. A registered clinical trial (or investigator-initiated trial, IIT) is a separate pathway from an approved, commercially available drug or therapy, with its own screening process and its own cost structure.

A "no match today" result is not permanent — trials open and close continuously, and a case can be re-checked as circumstances change.

The process is typically remote and free to start — you do not need to travel to China, and initial case review is commonly offered before any cost is discussed.

Introduction

Most people who look up a clinical trial matching service in China are in one of two situations. Either a doctor has said that standard treatment options are exhausted or aren't working, and someone in the family has heard that China has become one of the largest hubs for clinical trials and experimental cancer treatment worldwide — or a patient has already tried searching a trial registry directly, found dozens of listings in unfamiliar medical language, and has no way to tell which ones (if any) actually apply to their case.

What you're really asking is some combination of: Is this a real, legitimate service, or is it a scam? How does it actually work? Will it tell me whether I qualify for anything? What will it cost? What do I need to send them? And what happens if there's nothing available for my case?

This article answers those questions directly, in the order most people ask them.

What a China Clinical Trial Matching Service Is

A clinical trial matching service reviews a patient's diagnosis, treatment history, and current medical status, and compares it against the eligibility criteria of clinical trials that are currently open and enrolling in China. The output is a short, clinically relevant list of trials (and the hospitals running them) that a patient may realistically qualify for — instead of the hundreds of registered studies that show up in a general search of China's trial registry (ChiCTR), most of which won't apply to any one person's specific cancer, stage, or treatment history.

It is a screening and coordination process, not a guarantee of a trial spot. The service narrows the field; the hospital running the trial makes the actual enrollment decision.

Is This Different From Just Contacting a Hospital Directly?

In practice, yes, for two reasons.

First, trials for the same cancer type are frequently spread across multiple hospitals, each running a different protocol with different criteria. Contacting one hospital only tells you what's open there — not what's open elsewhere that might fit your case better.

Second, trial listings themselves are written in dense clinical and regulatory language (inclusion/exclusion criteria, biomarker requirements, prior-line-of-therapy definitions) that isn't written for patients or families to interpret without a medical background. A matching process exists specifically to translate a patient's real medical file into that language and check it against multiple protocols at once, rather than leaving a family to do that comparison itself, in a second language, while also managing a cancer diagnosis.

How the Matching Process Works

1. Your medical information is reviewed first

This starts with your actual medical record: diagnosis and subtype, stage, molecular or genetic markers if you've had that testing, your complete treatment history (what you've tried and how the cancer responded), and your current organ and blood function. If you have a blood cancer, whether your disease is relapsed or refractory, and how many prior treatment lines you've had, matters enormously — many trials are only open to patients who have already exhausted standard options.

2. Your profile is checked against currently open trials

Your case is then compared against registered, actively enrolling trials — not just by cancer type, but against each trial's specific inclusion and exclusion criteria. Two trials for what looks like "the same" cancer can have completely different eligibility windows, so this comparison has to happen protocol by protocol, not by diagnosis category alone. A 2024 study evaluating an AI-assisted matching system in Chinese patients with liver cancer found that automated screening against medical record data could meaningfully narrow the list of candidate trials before a human reviewed it — while also confirming that this kind of automated first pass isn't a substitute for that human and clinical review.

3. Options are compared across hospitals, not limited to one

Because relevant trials often exist at more than one hospital, this step looks across institutions rather than defaulting to whichever hospital happens to be best known internationally. The question being answered is which hospital has an actively enrolling protocol that fits your specific case.

4. The hospital's own investigators confirm eligibility

Whatever shortlist comes out of the steps above still has to be confirmed by the hospital running the trial. This is the step where your full case file — records, imaging, pathology, translated treatment history — gets reviewed by the actual clinical team who will decide whether you're eligible. No matching service can make that final call on the hospital's behalf. Once a trial has confirmed your eligibility, the practical steps of how to join a cancer clinical trial in China — consent, screening visits, and enrollment logistics — follow a separate process of their own.

Clinical Trials vs. Commercial Treatment: Why the Distinction Matters

If you're weighing "should I look for a trial" against "should I look for an already-approved treatment," it helps to know these are genuinely different pathways with different costs and different processes.

	Commercial treatment (e.g., approved CAR-T)	Clinical trial / investigator-initiated trial (IIT)
Regulatory status	Approved by China's NMPA and commercially available	Registered study; not a commercially approved product
Typical cost	Roughly $100,000–$150,000 USD total cost of care for CAR-T, as a standing figure across current published sources	Highly protocol-specific — some trials reduce or fully cover the cost of the drug itself, others don't. Any general number here would be a guess, not a fact
Eligibility screening	Standard clinical qualification (relapsed/refractory status, prior treatment lines, overall fitness)	The same baseline, plus criteria set by that specific trial's sponsor
Where it's available	Any hospital offering the approved treatment	Only the hospital(s) actively running that specific trial

The reason this article won't give you a single dollar figure for "clinical trials" as a category is that there isn't one honest number to give. Trial cost-sharing depends entirely on the specific protocol. By contrast, CAR-T therapy cost in China for commercially approved products is well-documented enough to state as a standing figure — which is exactly why the two shouldn't be quoted with the same level of confidence. A coordinator or the enrolling hospital can tell you the actual terms once you've been matched to a specific trial — that's a fair question to ask early, and you should ask it before assuming a trial will be cheaper (or more expensive) than commercial treatment.

What You'll Need to Provide

Having the following ready shortens the process, though none of it needs to be perfectly organized before you reach out:

• Pathology report, including molecular or genetic testing results if you've had them

• Complete treatment history — what drugs or therapies you've had, when, and how your cancer responded

• Most recent imaging (CT, MRI, or PET scans) and recent lab work

• A general sense of your current day-to-day functional ability

• If you have a blood cancer: whether it's considered relapsed or refractory, and how many prior lines of treatment you've had

If your records are incomplete, scattered across different doctors, or not in English, that's a normal starting point, not a disqualifying one — sorting and translating exactly this kind of documentation is part of what the process involves.

What to Expect If There's No Match Right Now

This is worth saying plainly, because it happens: not every case matches an open trial, and that's a possible outcome of an honest process, not a sign that something went wrong. Trials open and close continuously, so "no match today" doesn't mean "no match ever" — your case can be checked again later as new trials open or as your own situation changes. In the meantime, standard (non-trial) treatment options remain a separate, parallel path worth discussing with your treating oncologist.

It's also worth knowing that some trials carry nationality- or ethnicity-linked eligibility restrictions, tied to drug metabolism data or specific regulatory requirements. When that applies, it's part of the trial's published criteria — not something a matching process can work around.

And throughout all of this, a matching service is meant to inform the conversation you're having with your own oncologist, not replace it. The goal is to put realistic, verified options in front of you and your doctor together.

How ChinaCureLink Supports Trial Matching

ChinaCureLink runs this matching process for patients across the world, in partnership with the same network of Grade 3A hospitals covered in our broader guide to cancer treatment in China, rather than a single facility. In practical terms, that means:

• A free initial case review. Records and a summary of your diagnosis and treatment history are reviewed before any cost is discussed, so you know whether trial matching is realistic for your case before committing to anything.

• A multi-hospital comparison, not a single referral. Because relevant trials are frequently spread across more than one institution, your case is checked against options at several partner hospitals rather than being routed to whichever one the service happens to work with most.

• Translation and document handling. Pathology reports, imaging, and treatment histories are translated and organized into the format Chinese hospital investigators need to review a case efficiently — this is typically the slowest part of the process when families attempt it alone.

• Ongoing reassessment, not a one-time check. If no trial is currently open for your case, it's flagged for review again as new protocols open, rather than closed out permanently.

• Coordination that continues past matching. For cases that do proceed, the same team that handled the trial search also coordinates visa documentation, travel logistics, and communication with the treating hospital through treatment and follow-up.

Submitting a case for review does not commit you to treatment in China — it's a way to find out, concretely, whether a relevant trial exists before deciding anything further.

What Patients Say About ChinaCureLink & Medebound HEALTH

China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.

Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot

Medebound HEALTH's online testimonials. Learn More

★★★★☆   Sarah Zhang  ·  Canada· Jul 2024  ·  Verified

“The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.”

★★★★★   Andrew Goh  ·  Singapore · Aug 2024  ·  Verified

“My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.”

Frequently Asked Questions

What is a clinical trial matching service?

A process that reviews your diagnosis, treatment history, and current health status against the eligibility criteria of currently open, registered cancer clinical trials in China, and narrows a long, constantly changing list of studies down to the ones you may realistically qualify for.

Is clinical trial matching the same as being enrolled in a trial?

No. Matching identifies likely candidate trials and hospitals. The hospital running the trial makes the final enrollment decision after its own investigators review your complete case.

Does clinical trial matching cost anything?

Initial case review is commonly offered before any cost is discussed. Whatever costs follow relate to the treatment or trial itself, not the matching step — but arrangements can vary, so it's worth confirming directly before you share detailed records.

What if I don't qualify for any trial right now?

Trial availability changes regularly. A case that doesn't match today can be reassessed as new trials open or as your clinical status changes — and standard treatment remains a separate option in the meantime.

Do I need to travel to China to be matched to a trial?

No. Matching is typically done remotely, based on medical records and imaging you submit electronically. Travel usually only becomes necessary once a specific trial has confirmed your eligibility.

How is this different from searching China's clinical trial registry myself?

You can search China's registry (ChiCTR) directly, but listings are written for clinical and regulatory audiences, not patients — figuring out which of the results actually apply to your case usually requires someone who can read a protocol's inclusion/exclusion criteria against your specific medical file. That comparison is the core of what a matching process does.

References

1. Wang K, Cui H, Zhu Y, et al. Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study. BMC Cancer, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885498/

2. Re-analysis of the current status of clinical trial registration in China (ChiCTR). Frontiers in Medicine, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826807/

3. China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2- Advanced Gastric/GEJ Adenocarcinoma — OncLive, 2026. https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma

4. Medebound Reviews — Trustpilot. https://www.trustpilot.com/review/medebound.com

About ChinaCureLink

ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.

We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.

ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.

This article is for informational purposes only and is not medical or financial advice. Trial eligibility, protocol terms, and costs are specific to each hospital and study. Confirm all details with a patient coordinator and a treating oncologist before making any decisions.